In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the ...

Learn about cost and Ofev, financial and insurance assistance, ways to lower long-term costs, and more.

Oral nintedanib is associated with significant tolerability challenges, including diarrhea, hyperbilirubinemia, and drug-induced liver injury.

Gyre Therapeutics reported Q1 2025 revenue of $22.1 million and provided updates on clinical trials and product launches.

Patients who completed an open-label drug–drug interaction study of nintedanib and Microgynon (ethinylestradiol and levonorgestrel), in which female patients with SSc-ILD received nintedanib over a ...

Background Nintedanib was approved in the UK for use in progressive fibrosing interstitial lung disease (PF-ILD) in November 2021. The UK prescribing criteria were informed by the PF-ILD diagnostic ...

The following is a summary of “Nintedanib in rheumatoid arthritis related interstitial lung disease: real-world safety profile and risk of side effects and discontinuation,” published in the December ...

Results In the period from drug launch to 23 October 2015, 6,758 patients were treated with nintedanib, with duration of exposure 6 to 390 days (median 113 days). This analysis will present 1-year ...

Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China Objectives: This study aims to investigate adverse events (AEs) and adverse drug reactions (ADRs) ...

Nintedanib and pirfenidone can significantly slow lung function decline in IPF and have a better safety profile than other IPF drugs.